AIDS vaccine: Efficacy, safety and ethics
Abstract
Human immunodeficiency virus (HIV) has infected 50 million people worldwide and killed 16 million so far, and the epidemic is still spreading with 16,000 new cases of HIV infection daily and a projection of 100million infected individuals by the end of the next decade. There is no question that a safe and effective acquired immunodeficiency syndrome (AIDS) vaccine is urgently needed to bring the current AIDS pandemic under control. But, is preventive AIDS vaccine an attainable goat? Unfortunately, the results of many laboratory and clinical studies over the past two decades are not encouraging. We comment on the efficacy, safety and ethics of AIDS vaccine, and the urgent need for a new strategy for AIDS vaccine development. (c) 2007 Elsevier Ltd. All. rights reserved.
Keywords:
AIDS vaccine / safety / efficacySource:
Vaccine, 2008, 26, 24, 3072-3077Note:
- 1st International Symposium on Genetic and Immune Correlates of HIV Infection and Vaccine-Induced Immunity, Jun 10-13, 2007, Budapest, Hungary
DOI: 10.1016/j.vaccine.2007.11.061
ISSN: 0264-410X
PubMed: 18164521
WoS: 000257480100014
Scopus: 2-s2.0-44649127333
Collections
Institution/Community
VinčaTY - JOUR AU - Veljković, Veljko AU - Veljković, Nevena V. AU - Glišić, Sanja AU - Ho, Mae-Wan PY - 2008 UR - https://vinar.vin.bg.ac.rs/handle/123456789/6771 AB - Human immunodeficiency virus (HIV) has infected 50 million people worldwide and killed 16 million so far, and the epidemic is still spreading with 16,000 new cases of HIV infection daily and a projection of 100million infected individuals by the end of the next decade. There is no question that a safe and effective acquired immunodeficiency syndrome (AIDS) vaccine is urgently needed to bring the current AIDS pandemic under control. But, is preventive AIDS vaccine an attainable goat? Unfortunately, the results of many laboratory and clinical studies over the past two decades are not encouraging. We comment on the efficacy, safety and ethics of AIDS vaccine, and the urgent need for a new strategy for AIDS vaccine development. (c) 2007 Elsevier Ltd. All. rights reserved. T2 - Vaccine T1 - AIDS vaccine: Efficacy, safety and ethics VL - 26 IS - 24 SP - 3072 EP - 3077 DO - 10.1016/j.vaccine.2007.11.061 ER -
@article{ author = "Veljković, Veljko and Veljković, Nevena V. and Glišić, Sanja and Ho, Mae-Wan", year = "2008", abstract = "Human immunodeficiency virus (HIV) has infected 50 million people worldwide and killed 16 million so far, and the epidemic is still spreading with 16,000 new cases of HIV infection daily and a projection of 100million infected individuals by the end of the next decade. There is no question that a safe and effective acquired immunodeficiency syndrome (AIDS) vaccine is urgently needed to bring the current AIDS pandemic under control. But, is preventive AIDS vaccine an attainable goat? Unfortunately, the results of many laboratory and clinical studies over the past two decades are not encouraging. We comment on the efficacy, safety and ethics of AIDS vaccine, and the urgent need for a new strategy for AIDS vaccine development. (c) 2007 Elsevier Ltd. All. rights reserved.", journal = "Vaccine", title = "AIDS vaccine: Efficacy, safety and ethics", volume = "26", number = "24", pages = "3072-3077", doi = "10.1016/j.vaccine.2007.11.061" }
Veljković, V., Veljković, N. V., Glišić, S.,& Ho, M.. (2008). AIDS vaccine: Efficacy, safety and ethics. in Vaccine, 26(24), 3072-3077. https://doi.org/10.1016/j.vaccine.2007.11.061
Veljković V, Veljković NV, Glišić S, Ho M. AIDS vaccine: Efficacy, safety and ethics. in Vaccine. 2008;26(24):3072-3077. doi:10.1016/j.vaccine.2007.11.061 .
Veljković, Veljko, Veljković, Nevena V., Glišić, Sanja, Ho, Mae-Wan, "AIDS vaccine: Efficacy, safety and ethics" in Vaccine, 26, no. 24 (2008):3072-3077, https://doi.org/10.1016/j.vaccine.2007.11.061 . .